TDEY DD
TDEY (3D ENTERTAINMENT HOLDINGS, INC.) .0046 *BREAKING NEWS * http://online.wsj.com/article/PR-CO-20131205-...html?dsk=y 3D Eye Entertainment Holdings, Inc. Signs a Joint Venture Deal With Jasper Group Holdings Inc.
Breaking it down
... ,
TDEY has basically signed a joint venture with Jasper Group Holdings, Inc.
GOAL: For both companies to collaborate on launching a MOBILE APPLICATION
WHAT DOES THIS MOBILE APP DO? It provides educational videos to job seekers and acts as an interface for JGH's job channel Network recruiting video services and Candidate Exchange Placement service application (on the APP)
HOW DOES THIS FURTHER TIE IN WITH TDEY? The app will use 3D Eye Solutions technology to display video contentin simulated 3D format creating job feeds for the App for placement as well as online advertising for the App itself.
HOW IS THIS FINANCIALLY VIABLE?The Job Channel Network will integrate its content into the app library and money will be made on advertising and fee based job orders.
WHO OWNS JASPER GROUP HOLDINGS and its entities?
1) New York State's 55th Governor, David A. Paterson
2) Joe Abrams co-founder of MYSPACE
3) Michael Woloshin- owner of former company Candidates On Demand,
which grew to 6,700% from 2003-2006 from $250,000 to $17 million in REVENUE!
"We have 22 million unemployed and 3.4 million jobs that nobody can fill so I think it would be an interesting
place for people to go to get information," Governor David Patterson talks JCN on FOX 5 News.
About 3D Entertainment Holdings, Inc.
TDEY (OTC Pink: TDEY) is fully focused on a 2D and 3D content media creation business with distribution of content
through application and smart devices. Owner and developer of App3DTV found on smart devices which provide media
content and entertainment. More information can be found on www.App3DTV.com .
App3DTV is 2D and 3D app available on Smart Mobile devices for $7.99 per month. The application that features
3D movies, music videos, and other media all at your finger tips. It is currently on schedule to be on Roku and
Apple shortly. To download the app go to: www.App3dTV.com or directly from Android Play market:
http://goo.gl/Gy3hLG .
About Jasper Group Holdings, Inc.
Jasper Group Holdings, Inc. (the "Company") has developed several state-of-the-art transactional platforms for job placement, which allow employers, recruiters and applicants to optimally transact the entire job hiring process in real time. Employers and recruiters can interview, communicate, and/or reject applicants, book interviews and communicate with the touch of a button right from the resume platform all while utilizing industry best practices. Job seekers can see all activity as it relates to their resume, including job offers, resume submittals to companies, and more in real time. Recruiters can transact and interact with other recruiters all over the world to fill their own unfilled jobs as well as to screen more applicants for fee-based jobs. Dozens of additional features are on all sites designed to create an environment optimizing the hiring process.
In addition, for the companies that cannot afford full-service recruiters, it has created NameYourFee.com -- where companies can name their own fee to get the job filled. The system will then send out the job to those recruiters that match. Its goal is to revolutionize the industry by finally taking recruiting into the future with state of the art technology.
JGH Contact Information: Marketing Contact: Chris Petix, Chief Marketing Officer, chris.petix@jaspergroupinc.com,
646-234-1803 or For Investor Contact: Craig McGuinn, Dir. Strategic Partnerships, craig.mcguinn@jaspergroupinc.com
, 914-787-8171
Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
3DE Contact information:
Clark Ortiz
IR@TDEY.com
214-418-6940
STELLA DIAGNOSTICS INC. (SLDX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...
Continue Reading
Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...
Continue Reading
Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...
Continue Reading
Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...
Continue Reading
Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...
Continue Reading
Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...
Continue Reading
Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...
Continue Reading
Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...
Continue Reading
A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...
Continue Reading
New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Anika Therapeutics's Upcoming Earnings Anika Therapeutics (NASDAQ: ANIK) is scheduled to unveil its quarterly earnings report soon. This anticipation is palpable amongst investors who are eager to discover the latest financial insights that the company has to offer. As the date approaches, many are analyzing the potential earnings and what they might mean...
Continue Reading
QYOU Media Completes Sale of Q TV Broadcast Channel QYOU Media Inc., a leading player in the global creator economy, has successfully completed the sale of its free-to-air broadcast channel known as Q TV. This strategic move, executed through its subsidiary QYOU Media India Pvt. Ltd., marks a significant shift towards embracing new growth avenues focused on social media...
Continue Reading
Key Disclosure Information by Octopus Investments PUBLIC DISCLOSURE OF INVESTMENT INTERESTS In line with market regulations, Octopus Investments Ltd reveals crucial data regarding interests in relevant securities, particularly concerning Marlowe plc. This disclosure adheres to Rule 8.3 of the Takeover Code, aimed at maintaining transparency in the investment community....
Continue Reading
LiTime Introduces H190 Series Batteries for RV Enthusiasts At a recent trade show, LiTime made quite the impression with its first participation in Europe’s premier RV exhibition, the Il Salone del Camper. The event, which boasts a large turnout, allowed the company to spotlight its innovative H190 series of batteries tailored for motorhomes. Targeted Designs for Unique...
Continue Reading
Oncolytics Biotech Welcomes New Leadership for Future Growth Oncolytics Biotech Inc. (NASDAQ: ONCY), a notable player in the clinical-stage biotechnology sector focused on immunotherapy for cancer treatment, has proudly appointed Jared Kelly as its new Chief Executive Officer and as a member of its Board of Directors. This significant transition marks a pivotal moment for...
Continue Reading